Form 4: Rhythm Pharma CFO Sells Shares Under 10b5-1 Plan

Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, sold 6,628 shares of common stock for approximately $702,819 across multiple transactions in early February 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported the sale of 6,628 shares of common stock.
• The sales occurred on February 4, 2026, and February 5, 2026.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Smith on February 28, 2025.
• The shares were sold at weighted average prices ranging from $104.7434 to $107.6654 per share.
• Following these transactions, Mr. Smith beneficially owns 125,537 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale reduces executive ownership, its execution under a pre-established 10b5-1 plan suggests routine financial planning rather than a reaction to new, adverse company developments.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 plan, indicating a planned divestment rather than a reaction to new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the direct equity stake of a key executive in the company.

Industry Context

StockSavvy.ai notes that insider sales, particularly by C-suite executives, are routinely monitored by investors for potential signals about management's confidence in the company's future. However, sales executed under a Rule 10b5-1 plan, as in this case, are generally pre-scheduled and often for personal financial planning purposes, which typically mitigates the negative signaling effect compared to unscheduled sales.

Stakeholder Impact

• Shareholders may interpret the sale as a slight reduction in insider confidence, though the 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

The insider sale by the CFO, while reducing direct ownership, was executed under a pre-arranged 10b5-1 plan. This suggests a planned financial event rather than a reaction to new company-specific information, thus not warranting a change in investment thesis based solely on this filing. Investors should continue to hold and monitor broader company performance and industry trends.

Keywords

Rhythm Pharmaceuticals, RYTM, Hunter C. Smith, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals